Summit Therapeutics Inc. filed a Form 8-K on September 14, 2026, disclosing that its partner Akeso Inc. announced the presentation of updated data, including overall survival, from the Phase III HARMONi-2 trial at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer.

Key Highlights

  • Event date: Updated HARMONi-2 trial data is being presented on September 15, 2026.
  • Conference: The presentation is at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer.
  • Data type: Updated data includes overall survival from the randomized, double-blind Phase III HARMONi-2 trial.
  • Partner announcement: Akeso Inc., Summit Therapeutics' partner, made the announcement.
  • Press release attached: A press release dated September 13, 2026 is filed as Exhibit 99.1.

HARMONi-2 Overall Survival Data to Be Presented at 2026 Lung Cancer Conference

According to the filing, Summit Therapeutics Inc. (NASDAQ:SMMT) issued a press release on September 13, 2026 noting that Akeso Inc., its partner, announced an upcoming data presentation from the HARMONi-2 clinical trial. The trial is described in the filing as a "randomized, double-blind Phase III" study, and the data being presented includes updated overall survival results.

The filing discloses that the presentation is scheduled for Tuesday, September 15, 2026 at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer. No additional details about the data content or results are included in the body of the 8-K itself; the substantive disclosure resides in the attached press release, Exhibit 99.1, which is incorporated by reference into the filing.

The Current Report was signed on September 14, 2026 by Manmeet S. Soni, identified in the filing as Chief Operating Officer, Chief Financial Officer and Director, serving as Principal Financial Officer. The filing was made under Item 8.01 (Other Events) of Form 8-K.

What Was Disclosed

Summit Therapeutics filed an 8-K disclosing that partner Akeso Inc. announced updated Phase III HARMONi-2 trial data, including overall survival, to be presented at a lung cancer conference on September 15, 2026. A press release is attached as Exhibit 99.1.